HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX: CANF ) with a Buy and raises the price target from $5 to $8.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.